Summary & Overview
HCPCS Level II J1552: Immune Globulin (alyglo) 500 mg Injection
HCPCS Level II code J1552 designates a 500 mg injection of immune globulin (alyglo), a biologic used for immunoglobulin replacement or immune modulation. Nationally, precise coding for immune globulin products drives accurate clinical documentation, claims processing, and cost tracking due to high unit costs and site-of-service variation. Clear identification of product-specific HCPCS codes is important for payers, providers, and patients managing therapy access and coverage.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1552 represents, how it is typically administered, and which sites of service are most common. The publication outlines expected benchmarks for code use, payer coverage considerations, and relevant policy or billing updates where applicable.
This summary equips clinicians, coders, and revenue-cycle managers with the clinical context and billing clarity needed for claims submission and benefit verification for immune globulin therapy. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1552 represents an injection of immune globulin (alyglo), 500 mg. This entry describes a biologic infusion/ injection product used for immunoglobulin replacement or immune modulation.
-
Service Type: Injectable biologic therapy
-
Typical Site of Service: Infusion center, outpatient clinic, or physician office
Clinical & Coding Specifications
Clinical Context
Atypical patient: a 45-year-old female with primary humoral immunodeficiency presents to the ambulatory infusion clinic for intravenous immune globulin therapy. The order is for J1552 (injection, immune globulin (alyglo), 500 mg) to be administered as part of a regular replacement schedule every 3–4 weeks. The patient is assessed at check-in for vital signs and recent infections; allergies and prior infusion reactions are reviewed. An infusion nurse verifies weight-based dosing, reconstitutes and inspects the product, obtains informed consent for infusion, establishes peripheral IV access or uses a port, programs the infusion pump per manufacturer and protocol, and initiates therapy at a slow rate for the first 15–30 minutes while monitoring for adverse reactions (headache, fever, hypotension, anaphylaxis). Vital signs are recorded at baseline and periodically during and after the infusion. If an infusion reaction occurs, the nurse follows protocol, documents interventions, and may apply modifier 59-equivalent logic for separate services in documentation (note: 59 is not in the modifier list). After completion, the nurse documents lot numbers, administered units of J1552, and the patient is observed for delayed reactions before discharge with follow-up arranged with the ordering immunologist or allergist.
Coding Specifications
| Modifier | Description | When to Use |
|---|